Clinical trials: Relapsed/Refractory Non-Hodgkin Lymphoma
Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia
Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies
The purpose of this study is to evaluate the safety and effectiveness of TGR-1202 in patients with advanced hematologic malignancies.
- Conditions
- Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Peripheral T-Cell Lymphoma, Hodgkin's Lymphoma
- Trial name
- NCT01767766
- Testing
- TGR-1202
- Where
- 7 sites in United States
- Volunteers
- 90 people
- Sponsor
- TG Therapeutics, Inc.
Lymphoma, Follicular
An Efficacy and Tolerability Study of Bortezomib in Combination With Rituximab Standard Therapy in Participants With Relapsed or Refractory Follicular Lymphoma
The purpose of this study is to evaluate the efficacy (effectiveness) and tolerability (how well a participant can stand a particular medicine or treatment; ability to be used) of bortezomib in combination with rituximab standard…
- Trial name
- NCT01902862
- Testing
- Bortezomib, Rituximab
- Where
- 3 sites in Germany
- Volunteers
- 7 people
- Sponsor
- Janssen-Cilag G.m.b.H
Follicular Lymphoma (FL)
A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma
The purpose of this study is to evaluate the efficacy and safety of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular lymphoma (FL).
- Trial name
- NCT07562022
- Testing
- SCTB35 injection, Rituximab, Lenalidomide
- Where
- China
- Volunteers
- 93 people
- Sponsor
- Sinocelltech Ltd.
Relapsed/Refractory Follicular Lymphoma, Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)
A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
This study is researching an experimental drug called odronextamab (referred to as study drug), in combination with lenalidomide.
- Trial name
- OLYMPIA-5 (NCT06149286)
- Testing
- Odronextamab, Lenalidomide, Rituximab
- Where
- 171 sites in United States, Australia and 16 more
- Volunteers
- 580 people
- Sponsor
- Regeneron Pharmaceuticals
NHL, Cutaneous T Cell Lymphoma
A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lymphoma (CTCL), Testing the Safety and Activity of a Novel Drug to Inhibit a Protein Called Tumor Necrosis Factor Receptor 2 That Drives Both Lymphoma Growth and Escape of the Immune System
The goal of this trial is to learn if a new drug, BITR2101, works to treat non-Hodgkin lymphoma (NHL) in adults, with CTCL patients being sought in particular. The trial also seeks to learn about the safety of this drug.
- Conditions
- NHL, Cutaneous T Cell Lymphoma, Peripheral T-cell Lymphoma
- Trial name
- NCT06385522
- Testing
- BITR2101
- Volunteers
- 37 people
- Sponsor
- Boston Immune Technologies and Therapeutics
Non-Hodgkin's Lymphoma, Diffuse Large B-cell Lymphoma
Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL
This was a Phase 1/2 study performed at two clinical centers in the US and UK. It was a single arm, open label study evaluating VSLI plus rituximab in adults with aggressive relapsed or refractory non-Hodgkin's lymphoma.
- Conditions
- Non-Hodgkin's Lymphoma, Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma
- Trial name
- NCT01851551
- Testing
- Vincristine Sulfate Liposome Injection plus rituximab
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 22 people
- Sponsor
- Acrotech Biopharma Inc.
Non-Hodgkin's Lymphoma
F01 in the Treatment of Relapsed/Refractory Non-hodgkin's Lymphoma
This is a multicenter, open, Phase I clinical study to evaluate the safety and tolerability of F01 in subjects with relapsed/refractory non-Hodgkin lymphoma, and to determine MTD and/or RD.
- Trial name
- NCT06206902
- Testing
- After preconditioning with chemotherapy, F01 will be evaluated.
- Where
- 2 sites in China
- Volunteers
- 55 people
- Sponsor
- Shanghai Simnova Biotechnology Co.,Ltd.
DLBCL
Expanded Access Program for Tafasitamab (MOR00208) in R/R DLBCL
Expanded Access Program (EAP) to provide Tafasitamab (MOR208) to eligible patients with relapsed or refractory Diffuse Large B Cell Lymphoma.
- Trial name
- NCT04300803
- Testing
- Tafasitamab, 12 mg/kg. 4 week cycles: weekly (Cycle 1-3) to bi-weekly (Cycle 4 onwards), loading dose Cycle 1, day 4. Cycle 4 onwards day 1, day 15 until disease progression
- Sponsor
- MorphoSys AG
Follicular Lymphoma
Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma
This is a multi-center, phase II study to determine the efficacy and safety of tisagenlecleucel in adult patients with relapsed or refractory FL.
- Trial name
- ELARA (NCT03568461)
- Testing
- tisagenlecleucel
- Where
- 30 sites in United States, Australia and 10 more
- Volunteers
- 98 people
- Sponsor
- Novartis Pharmaceuticals
Lymphoma, Lymphoma, B-Cell
Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma
This is a Phase 1, multi-center, open-label study of TRPH-222 monotherapy in subjects with relapsed and/or refractory B-cell NHL. The study will be conducted in two Stages: Dose-Escalation, Dose-Expansion.
- Conditions
- Lymphoma, Lymphoma, B-Cell, Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell
- Trial name
- NCT03682796
- Testing
- TRPH-222
- Where
- 7 sites in United States, Canada
- Volunteers
- 32 people
- Sponsor
- Triphase Research and Development III Corp.
Leukemia, Lymphoma, Large B-Cell, Diffuse
CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma
This is a single arm study to evaluate the efficacy and safety of CD19-targeted CAR-T cells therapy for patients with relapsed/refractory CD19+ B Cell Leukemia and Lymphoma.
- Conditions
- Leukemia, Lymphoma, Large B-Cell, Diffuse, Leukemia, B-cell, Lymphoma, B-Cell
- Trial name
- NCT04271410
- Testing
- CD19 CAR-T cells
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
B-cell Non Hodgkin Lymphoma
A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Relapsed/ Refractory B-Cell Non-Hodgkin Lymphoma
This is an open-label, multiple ascending dose (MAD), phase 1 study in adult patients with relapsed or refractory (R/R) B cell non-Hodgkin lymphoma (B-NHL).
- Trial name
- NCT06392477
- Testing
- SAR448501
- Where
- 16 sites in Australia, Serbia and 3 more
- Volunteers
- 96 people
- Sponsor
- Sanofi
Chronic Lymphocytic Leukemia (CLL), Lymphoma, Non-Hodgkin (NHL)
Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies
The purpose of this study is to determine the dose that can be safely given to see what effect it may have on your cancer and to determine how the drug is distributed in the body.
- Conditions
- Chronic Lymphocytic Leukemia (CLL), Lymphoma, Non-Hodgkin (NHL), Acute Myeloid Leukemia (AML), Multiple Myeloma (MM)
- Trial name
- NCT00710528
- Testing
- CAL-101
- Where
- 9 sites in United States
- Volunteers
- 192 people
- Sponsor
- Gilead Sciences
Lymphoma, Non-Hodgkin, Relapsed Non Hodgkin Lymphoma
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and immunogenicity of CB-010 in adults with relapsed/refractory B cell non-Hodgkin lymphoma after lymphodepletion consisting of cyclophosphamide and…
- Conditions
- Lymphoma, Non-Hodgkin, Relapsed Non Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Non Hodgkin Lymphoma
- Trial name
- NCT04637763
- Testing
- CB-010, Cyclophosphamide, Fludarabine
- Where
- 38 sites in United States, Australia and 1 more
- Volunteers
- 72 people
- Sponsor
- Caribou Biosciences, Inc.
Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma
Brentuximab Vedotin (Recombinant) for IV Infusion - Special Drug Use Surveillance (All-case Surveillance) "Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma"
The purpose of this study is to evaluate the safety of brentuximab vedotin (recombinant) for intravenous (IV) infusion (ADCETRIS IV Infusion 50 mg) in patients with relapsed/refractory CD30+ Hodgkin's lymphoma or anaplastic large…
- Trial name
- NCT02139592
- Testing
- Brentuximab vedotin (recombinant)
- Where
- Japan
- Volunteers
- 292 people
- Sponsor
- Takeda
Non-hodgkin's Lymphoma
Clinical Study of SL19+22 CAR-T Cells for Relapsed or Refractory Non-Hodgkin Lymphoma
To evaluate the safety and efficacy of SL19+22 in patients with relapsed or refractory non-Hodgkin's lymphoma.
- Trial name
- NCT05206071
- Testing
- CD19+22 CAR-T cells
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
Non Hodgkin's Lymphoma Refractory/Relapsed
Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma
Open-label, Phase 1 Study of CD19 t-haNK as a Single Agent and in Combination With an IL-15 Superagonist (N-803) and Rituximab in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma.
- Trial name
- NCT05618925
- Testing
- N803, CD19t-haNK suspension, Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- ImmunityBio, Inc.
Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia, Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
The primary objectives of this study are to evaluate the safety and efficacy of brexucabtagene autoleucel (KTE-X19) in pediatric and adolescent participants with relapsed/refractory (r/r) B-precursor acute lymphoblastic leukemia…
- Trial name
- ZUMA-4 (NCT02625480)
- Testing
- Brexucabtagene Autoleucel (KTE-X19), Fludarabine, Cyclophosphamide
- Where
- 30 sites in United States, Belgium and 9 more
- Volunteers
- 95 people
- Sponsor
- Kite, A Gilead Company
Relapsed or Refractory T Cell Lymphoma
Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma
This study will investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ONO-4685 in patients with relapsed or refractory T cell Lymphoma
- Trial name
- NCT05079282
- Testing
- ONO-4685
- Where
- 21 sites in United States
- Volunteers
- 217 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas
This study is being done to evaluate the safety, tolerability and effectiveness of Oral CG-806 for the treatment of patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or Non-Hodgkin's Lymphomas…
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Non-Hodgkin's Lymphoma
- Trial name
- NCT03893682
- Testing
- CG-806
- Where
- 30 sites in United States
- Volunteers
- 36 people
- Sponsor
- Aptose Biosciences Inc.